Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17334643 | 0.85 | MAPK1 (0.56) | ALDH1A1MAOBTAAR1 | |
| SCHEMBL8908947 | 0.85 | ALDH1A1 (0.52) | ALDH1A1TAAR1AHRPLA2G2A | |
| SCHEMBL15923392 | 0.83 | MAPT (0.51) | MAOBTAAR1 | |
| SCHEMBL4030217 | 0.83 | MAPT (0.51) | MAOBTAAR1 | |
| SCHEMBL7237766 | 0.82 | MAPK1 (0.57) | ALDH1A1MAOBTAAR1 | |
| SCHEMBL6255090 | 0.81 | MAPT (0.53) | ALDH1A1MAOBTAAR1 | |
| SCHEMBL7390211 | 0.81 | ALDH1A1 (0.48) | ALDH1A1FFAR1PPARGPPARDPPARA | |
| SCHEMBL28360552 | 0.81 | PLA2G2A (0.59) | ALDH1A1MAOAMAOBAHRPLA2G2A | |
| Hydrazine SCHEMBL17334655 | 0.80 | MAPT (0.49) | MAOBTAAR1 | |
| SCHEMBL16447478 | 0.79 | TAAR1 (0.44) | TAAR1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6303641-B1 | FOR THERAPY AND PROPHYLAXIS OF DISEASES CHARACTERIZED BY ABNORMAL CELL DIFFERENTIATION AND/OR CELL PROLIFERATION SUCH AS PSORIASIS AND CANCER | LEO PHARMACEUTICALS PRODUCTS LTD. (DK) | 2001-10-16 | — | — | US | disclosed |
| EP-0984940-A1 | CYANOAMIDINES AS CELL PROLIFERATION INHIBITORS | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054147-A1 | CYANOAMIDINES AS CELL PROLIFERATION INHIBITORS | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1998-12-03 | — | — | WO | disclosed |
| US-5696140-A | FOR TREATMENT OF ASTHMA, ALLERGIES, NERVOUS SYSTEM DISORDERS OR CANCER | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1997-12-09 | — | — | US | disclosed |